Modeling and Simulation Archives

Publication

Interlaboratory Variability in the Madin–Darby Canine Kidney Cell Proteome

Madin–Darby canine kidney (MDCK) cells are widely used to study epithelial cell functionality. Their low…

Certara2023 年 6 月 28 日

Case Study

利用药代动力学建模和科学传播专长推进肉样瘤病药物项目

Certara's support, from dose optimization to medical writing, helps pharmaceutical companies advance their research, make…

Certara2023 年 6 月 1 日

Conference

American College of Toxicology 2025 Annual Meeting

– – Booth

Certara2023 年 5 月 24 日

Conference

ISPOR Europe 2025

–

Certara2023 年 5 月 24 日

Conference

ACoP 2025

Certara2023 年 5 月 24 日

Case Study

Using Modeling & Simulation to Develop a Dosing Regimen for a Bispecific Antibody for Pediatric Cancer

Bispecific antibodies are an emerging class of antibodies developed in recent years that provide new…

Certara2023 年 1 月 23 日

Conference

ACCP 年度会议

– – Booth

Certara2022 年 7 月 15 日

Case Study

Simcyp Simulator 有助于优化成人和青少年孤儿病患者的用药剂量

全世界约有 400,000 名先天性肾上腺增生症（CAH）患者。Current therapy for CAH uses a…

Certara2022 年 6 月 6 日

Case Study

Bridging Formulations of Quetiapine for Children with Schizophrenia or Bipolar Disorder

Quetiapine is an atypical antipsychotic for treating schizophrenia, bipolar depression, bipolar mania that helps to…

Certara2021 年 8 月 26 日

Case Study

Aripiprazole lauroxil: PBPK for Dosing Regimen and DDI Identification

Aripiprazole lauroxil (Aristada®) was approved by the FDA for treating schizophrenia in adults in October…

Certara2021 年 8 月 12 日

建模与模拟

Interlaboratory Variability in the Madin–Darby Canine Kidney Cell Proteome

利用药代动力学建模和科学传播专长推进肉样瘤病药物项目

American College of Toxicology 2025 Annual Meeting

ISPOR Europe 2025

ACoP 2025

Using Modeling & Simulation to Develop a Dosing Regimen for a Bispecific Antibody for Pediatric Cancer

ACCP 年度会议

Simcyp Simulator 有助于优化成人和青少年孤儿病患者的用药剂量

Bridging Formulations of Quetiapine for Children with Schizophrenia or Bipolar Disorder

Aripiprazole lauroxil: PBPK for Dosing Regimen and DDI Identification

订阅时事通讯

快捷链接

解决方案

联系我们